[
    [
        {
            "time": "2020-08-15",
            "original_text": "康泰生物(300601)2020年中报点评：二季度业绩恢复快速增长 在研产品逐步迎来收获期",
            "features": {
                "keywords": [
                    "康泰生物",
                    "二季度",
                    "业绩增长",
                    "在研产品",
                    "收获期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "康泰生物(300601)2020年中报点评：二季度业绩恢复快速增长 在研产品逐步迎来收获期",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-07-30",
            "original_text": "125家药企半年报预告出炉，康泰生物Q2环比100倍增长，药明康德、华海药业",
            "features": {
                "keywords": [
                    "康泰生物",
                    "Q2",
                    "环比增长",
                    "药明康德",
                    "华海药业"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "125家药企半年报预告出炉，康泰生物Q2环比100倍增长，药明康德、华海药业",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-09-05",
            "original_text": "现金流大降八成 3年股价涨近50倍的康泰生物估值贵了？",
            "features": {
                "keywords": [
                    "康泰生物",
                    "现金流下降",
                    "估值",
                    "股价上涨"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "现金流大降八成 3年股价涨近50倍的康泰生物估值贵了？",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 10,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-09-10",
            "original_text": "康泰生物现金流大降八成 公司称形成坏账可能性较小｜公司问答 运营能力下降",
            "features": {
                "keywords": [
                    "康泰生物",
                    "现金流下降",
                    "坏账风险",
                    "运营能力"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物现金流大降八成 公司称形成坏账可能性较小｜公司问答 运营能力下降",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-08-20",
            "original_text": "康泰生物上半年净利润持平 10亿投新型疫苗研发产业化",
            "features": {
                "keywords": [
                    "康泰生物",
                    "净利润持平",
                    "新型疫苗",
                    "研发投入"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "康泰生物上半年净利润持平 10亿投新型疫苗研发产业化",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-08-25",
            "original_text": "康泰生物(300601)2020年中报点评：四联苗加速恢复 23价贡献业绩弹性",
            "features": {
                "keywords": [
                    "康泰生物",
                    "四联苗",
                    "23价疫苗",
                    "业绩弹性"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "康泰生物(300601)2020年中报点评：四联苗加速恢复 23价贡献业绩弹性",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-09-01",
            "original_text": "康泰生物：四联苗销量恢复快速增长，乙肝疫苗短期拖累业绩",
            "features": {
                "keywords": [
                    "康泰生物",
                    "四联苗",
                    "乙肝疫苗",
                    "业绩拖累"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "scores": {
                "News_content": "康泰生物：四联苗销量恢复快速增长，乙肝疫苗短期拖累业绩",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-08-30",
            "original_text": "康泰生物二季度业绩超去年同期 12个在研项目进入注册程序",
            "features": {
                "keywords": [
                    "康泰生物",
                    "二季度",
                    "业绩增长",
                    "在研项目",
                    "注册程序"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "康泰生物二季度业绩超去年同期 12个在研项目进入注册程序",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-09-15",
            "original_text": "康泰生物二季度业绩 狂飙逾六成 机构抱团1370亿估值是否“高处不胜寒”？",
            "features": {
                "keywords": [
                    "康泰生物",
                    "二季度",
                    "业绩增长",
                    "机构抱团",
                    "估值"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物二季度业绩 狂飙逾六成 机构抱团1370亿估值是否“高处不胜寒”？",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 10,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-09-20",
            "original_text": "刘格菘重仓股康泰生物扭转局面业绩微增 回款能力减弱现金流巨降",
            "features": {
                "keywords": [
                    "康泰生物",
                    "刘格菘",
                    "业绩微增",
                    "回款能力",
                    "现金流下降"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "刘格菘重仓股康泰生物扭转局面业绩微增 回款能力减弱现金流巨降",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-09-25",
            "original_text": "康泰生物Q2业绩狂飙逾六成 机构对其估值现分歧",
            "features": {
                "keywords": [
                    "康泰生物",
                    "Q2",
                    "业绩增长",
                    "机构分歧",
                    "估值"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物Q2业绩狂飙逾六成 机构对其估值现分歧",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]